Purpose The aim of this study was to test the ability of paclitaxel-loaded poly
(butylcyanoacrylate)(PBCA) nanoparticles to overcome multidrug resistance (MDR) in …

The aim of the present study was to evaluate the efficacy of paclitaxel combined with
curcumin (CUR) against drug resistance in ovarian cancer cells. PLGA-phospholipid-PEG …

Paclitaxel (PTX) is frequently suffered from multidrug resistance (MDR), resulting in lower
chemotherapeutic efficacy and even chemotherapy failure. To combine the P-glycolprotein …

One of the main challenges of treatment of ovarian cancer is initial response to treatment
and then acquisition of resistance to Cisplatin. Nanotechnology-based approaches are …

Background Ovarian cancer is a common malignancy in the female reproductive system with
a high mortality rate. The most important reason is multidrug resistance (MDR) of cancer …

Adenocarcinoma is the most lethal gynecologic tumor and treatment usually consists in
surgery followed by chemotherapy. However, the chemotherapy benefits are eventually …

Development of multidrug resistance (MDR) against a variety of conventional and novel
chemotherapeutic agents is a significant challenge in effective cancer therapy. Over the last …

The objective of this study was to overcome drug resistance upon systemic administration of
combination paclitaxel (PTX) and the apoptotic signaling molecule C6‐ceramide (CER) in …

In this study, the effect of MDR-1 gene silencing, using small interfering RNA (siRNA), and
paclitaxel (PTX) co-therapy in overcoming tumor multidrug resistance was examined. Poly …

Abstract Development of multidrug resistance (MDR) is an almost universal phenomenon in
patients with ovarian cancer and this severely limits the ultimate success of chemotherapy in …